Search research articles
Contact Us
Filters
Showing results (11-20 of 58) with videos related to
Page
of 6
Sort By:
Statistics in Biopharmaceutical Research
|
March 12, 2010
Flexible Phase I Clinical Trials: Allowing for Nonbinary Toxicity Response and Removal of Other Common Limitations
Richard F Potthoff, Stephen L George
Journal of Biopharmaceutical Statistics
|
April 23, 2009
Between-arm comparisons in randomized Phase II trials
Sin-Ho Jung, Stephen L George
Statistics in Medicine
|
May 4, 2004
Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?
Susan S Ellenberg, Stephen L George
Biostatistics (Oxford, England)
|
June 23, 2012
ROC curve estimation under test-result-dependent sampling
Xiaofei Wang, Junling Ma, Stephen L George
Statistics in Biopharmaceutical Research
|
May 31, 2016
A Multi-state Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression
Fang Xia, Stephen L George, Xiaofei Wang
Statistics in Biopharmaceutical Research
|
August 4, 2025
Assessment of treatment effect heterogeneity for multiregional randomized clinical trials
Haotian Zhuang, Xiaofei Wang, Stephen L George
Journal of Biopharmaceutical Statistics
|
November 11, 2005
Sample size calculation for simulation-based multiple-testing procedures
Heejung Bang, Sin-Ho Jung, Stephen L George
Statistics in Medicine
|
September 29, 2005
A multiple testing procedure to associate gene expression levels with survival
Sin-Ho Jung, Kouros Owzar, Stephen L George
Statistics in Medicine
|
February 24, 2011
Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint
Stefan Michiels, Richard F Potthoff, Stephen L George
Controlled Clinical Trials
|
February 26, 2004
Data monitoring and large apparent treatment effects
Edward L Korn, Boris Freidlin, Stephen L George
Page
of 6
Search research articles
Search
Showing results (11-20 of 58) with videos related to
Sort By:
Page
of 6
Statistics in Biopharmaceutical Research
|
March 12, 2010
Flexible Phase I Clinical Trials: Allowing for Nonbinary Toxicity Response and Removal of Other Common Limitations
Richard F Potthoff, Stephen L George
Journal of Biopharmaceutical Statistics
|
April 23, 2009
Between-arm comparisons in randomized Phase II trials
Sin-Ho Jung, Stephen L George
Statistics in Medicine
|
May 4, 2004
Should statisticians reporting to data monitoring committees be independent of the trial sponsor and leadership?
Susan S Ellenberg, Stephen L George
Biostatistics (Oxford, England)
|
June 23, 2012
ROC curve estimation under test-result-dependent sampling
Xiaofei Wang, Junling Ma, Stephen L George
Statistics in Biopharmaceutical Research
|
May 31, 2016
A Multi-state Model for Designing Clinical Trials for Testing Overall Survival Allowing for Crossover after Progression
Fang Xia, Stephen L George, Xiaofei Wang
Statistics in Biopharmaceutical Research
|
August 4, 2025
Assessment of treatment effect heterogeneity for multiregional randomized clinical trials
Haotian Zhuang, Xiaofei Wang, Stephen L George
Journal of Biopharmaceutical Statistics
|
November 11, 2005
Sample size calculation for simulation-based multiple-testing procedures
Heejung Bang, Sin-Ho Jung, Stephen L George
Statistics in Medicine
|
September 29, 2005
A multiple testing procedure to associate gene expression levels with survival
Sin-Ho Jung, Kouros Owzar, Stephen L George
Statistics in Medicine
|
February 24, 2011
Multiple testing of treatment-effect-modifying biomarkers in a randomized clinical trial with a survival endpoint
Stefan Michiels, Richard F Potthoff, Stephen L George
Controlled Clinical Trials
|
February 26, 2004
Data monitoring and large apparent treatment effects
Edward L Korn, Boris Freidlin, Stephen L George
Page
of 6